Entheon Announces Continuance into British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's an
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-10-08 6:49 PM EDT | Entheon Biomedical Corp.
Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCID: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregate p
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-10-08 5:15 PM EDT | Psyched Wellness Ltd.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psyche
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-10-08 8:19 AM EDT | Rhelion Life Sciences Corp.
Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics" or the "Company") is pleased to announce the appointment of J. David Warren, Ph.D., as Chief Executive Officer and as a director of the Company, effective October 1st, 2026. Dr. Warren brings more than two decades of experience in bioorganic chemistry, medicinal chemistry, peptide science and translational drug discovery. He is an Adjunct Associate Professor
Household / Consumer / Cosmetics, Psychedelics
2026-10-02 7:30 AM EDT | Adaptogenics Health Corp.
Numinus Wellness Founders to Resume Original Executive Roles
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that its founders will resume their original executive leadership roles, effective October 1, 2026. Pay
2026-10-01 5:00 PM EDT | Numinus Wellness Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsid
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-29 7:53 AM EDT | Rhelion Life Sciences Corp.
Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce that, further to its news release dated August 14, 2026, the Company has closed its oversubscribed non-brokered private placement of 4,087,500 common shares (the "Shares") at a price of $0.08 per Share for aggregate gross proceeds of $327,000 (the "Private Placement"). The Company had
Household / Consumer / Cosmetics, Psychedelics
2026-09-28 4:40 PM EDT | Adaptogenics Health Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Toronto, Ontario--(Newsfile Corp. - September 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research with
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-25 8:48 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
Toronto, Ontario--(Newsfile Corp. - September 22, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion"
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-22 7:33 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization adv
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-21 7:49 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
Toronto, Ontario--(Newsfile Corp. - September 17, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly ow
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-17 7:52 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a supply and licensing agreement with the University of Southern California, on behalf of its Keck School of Medicine of USC, for t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-15 7:59 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and re
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-14 7:53 AM EDT | Rhelion Life Sciences Corp.
Entheon Adopts Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that it has elected to participate in the Coordinated Blanket Order 51-933 – Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order"), issued by the Canadian Securities Administrators, and adopts semi-annual financial reporting. This news release is being filed
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-09-11 6:18 PM EDT | Entheon Biomedical Corp.
Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregat
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-09-10 4:15 PM EDT | Psyched Wellness Ltd.
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic se
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-10 7:55 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund The study is the first trial of PEX010 in a movement disorder and, to the Company's kno
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-08 7:52 AM EDT | Rhelion Life Sciences Corp.
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-03 7:39 AM EDT | Rhelion Life Sciences Corp.
Numinus Wellness Inc. Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has filed all quarterly interim financial reports for fiscal year 2026 to May 31, 2026. With the re
2026-09-01 5:39 AM EDT | Numinus Wellness Inc.
Rhelion Life Sciences Reports First Quarter 2027 Results
Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ("Filament"). All figures are reported
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-08-31 8:39 AM EDT | Rhelion Life Sciences Corp.